Skip to main content
Premium Trial:

Request an Annual Quote

Navigenics Teams with ACPM on Genetic Risk CME Course

NEW YORK (GenomeWeb News) – Consumer genomics firm Navigenics said today that it is providing an unrestricted educational grant of an undisclosed amount to the American College of Preventive Medicine to develop a continuing medical education course entitled, “Genetic Risk, Screening, and Intervention.”
 
The course will seek to “improve physicians’ understanding of genetic risk factors for disease, the current evidence about the use of genomic tools and technologies to determine risk, and promising practices for utilizing those tools to aid in disease prevention,” the partners said in a statement.
 
They said that ACPM is working with its members and national experts in genomics, prevention, and epidemiology to design the course. ACPM expects the program to compare and contrast the evidence for genetic screening and risk factors to epidemiological approaches typically used to identify disease risk; explore the potential benefits and harms derived from different types of genetic tests; and examine current evidence around genome-association studies and provide a framework for evaluating the quality of such studies.
 
The course is expected to be available on the ACPM website and on DVD-ROM in early 2009.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.